HR-Positive, HER2-Negative Early Breast Cancer At High Risk of Recurrence

CME Activities

• Conceptualizing Guidelines to Manage Patients With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
  Medscape Education Oncology, March 2023
  What do the guidelines say about treating patients with early breast cancer at high risk for recurrence?
  0.75 CME

  0.75 ABIM MOC

  0.75 CE
• Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Guidelines
  Medscape Education Oncology, March 2023
  Which of the guidelines for use of CDK 4/6 inhibitors do you use to guide treatment for patients with HR-positive/HER2-negative early breast cancer?
  0.50 CME

  0.50 ABIM MOC
• Adjuvant Therapy in Hormone Receptor Positive/HER2-Negative Early Breast Cancer: Case Simulations
  Medscape Education Oncology, March 2023
  Do you know the best approaches for identifying and managing high-risk, hormone receptor positive early breast cancer?
  1.00 CME

  1.00 ABIM MOC
• Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding the Data and Their Implications
  Medscape Education Oncology, January 2023
  Will the newly reported monarchE data change your clinical practice for patients with HR+/HER- early breast cancer?
  0.50 CME

  0.50 ABIM MOC
• The Patient Journey in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Best Practices for Communication and Shared Decision-making
  Medscape Education Oncology, November 2022
  Do you know how best to discuss risk of recurrence and treatment approaches with patients? Can you effectively educate patients on potential adverse events (AEs)?
  0.50 CME

  0.50 CE
• Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Challenging Cases in the Clinic
  Medscape Education Oncology, November 2022
  How confident are you at identifying patients with hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence?
  0.50 CME

  0.50 ABIM MOC
• Improving Outcomes in Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer: Keeping the Patient Central
  Medscape Education, September 2022
  What are some practical ways to improve outcomes in patients with high-risk HR+/HER2- early breast cancer? Listen to the experts at ESMO to find out.
  1.25 CME

  1.25 ABIM MOC

  1.25 CE
• Virtual Grand Rounds for Nurses: Supporting the Patient With HR+/HER2-Breast Cancer
  Medscape Education, April 2022
  Do you know the most common side effects for CDK4/6 inhibitors and how to best manage them?
  0.50 CE

CNE Activities

• Cases From the Clinics: The Nurse's Role in Communicating on Adherence and Persistence in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
  Medscape Education, September 2022
  Expert faculty discuss clinical cases, emphasizing the importance of communication with patients on adherence to therapy.
• HR+/HER2- Early Breast Cancer: A Nurse Clinic on Monitoring and Communicating With Patients
  Medscape Education, September 2022
  Do you want to learn more about managing and monitoring adverse events, promoting adherence, and maintaining communication with patients with early breast cancer (EBC)?
• Adjuvant Therapies in HR+/HER2- Early Breast Cancer: A 3-Step Plan to Improve Adherence and Persistence
  Medscape Education, September 2022
  Learn how you can help patients with early breast cancer improve their adherence to and persistence with adjuvant therapy.